Niitaka Co., Ltd.
Financial Summary for the First Quarter of the Fiscal Year Ending May 2027 (Consolidated) [Japanese GAAP]
Sales were 6.34 billion yen, up 5.5% year over year. Operating income was 585 million yen (up 0.5%), ordinary income 608 million yen (down 1.2%), and net income attributable to owners of the parent 415 million yen (down 0.8%). Full-year guidance is unchanged. Chemicals segment performed well, while Healthcare slowed.
Key Figures
- Sales: 63,340 million yen (YoY +5.5%)
- Operating income: 585 million yen (YoY +0.5%)
- Net income attributable to owners of the parent: 415 million yen (YoY −0.8%)
AI要約
Summary of Business Results
For the first quarter of the consolidated fiscal year, net sales were 6.334 billion yen, up 5.5% year over year, and the business showed solid performance. However, impact from a slowdown in the Healthcare segment and higher raw material costs persisted, resulting in operating income of 58.5 million yen (up 0.5%), ordinary income of 60.8 million yen (down 1.2%), and net income attributable to owners of the parent of 41.5 million yen (down 0.8%). By segment, the Chemicals business expanded, while Healthcare saw a substantial decline in revenue and profit. Full-year guidance remains unchanged. No notable changes regarding share buyback in the body text.
Financial Position and Outlook
Total assets decreased from the end of the previous term, while net assets fluctuated mainly due to an increase in net income for the period and the effects of dividends and share buybacks. The financial structure is solid, but the underperformance of Healthcare is a concern. No change to the full-year earnings guidance. Going forward, trends in raw material costs and domestic and international demand recovery are expected to be key drivers of performance.
Niitaka Co., Ltd.
Company overview · Stock price · Financial data · All IR
